|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Exogenous plant MIR168a specifically targets mammalian LDLRAPI: evidence of cross-kingdom regulation by microRNA显示文摘 | Lin Zhang Dongxia Hou Xi Chen Donghai Li Lingyun Zhu Yuj ing Zhang Jing Li Zhen Bian Xiangying Liang Xing Cai Yuan Yin Cheng Wang Tianfu Zhang Dihan Zhu Dianmu Zhang Jie Xu Qun Chen Yi Ba Jing Liu Qiang Wang Jianqun Chen Jin Wang Meng Wang Qipeng Zhang Junfeng Zhang Ke Zen Chen-Yu Zhang | 2012 | Cell Research2012，22，1： | 155 |
| 2 | Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites显示文摘AIM:To investigate the procedure, feasibility and effects of laparoscopeassisted continuous circulatory hyperthermic intraperitoneal perfusion chemotherapy (CHIPC) in treatment of malignant ascites induced by peritoneal carcinomatosis from gastric cancers. METHODS: From August 2006 to March 2008, the laparoscopic approach was used to perform CHIPC on 16 patients with malignant ascites induced by gastric cancer or postoperative intraperitoneal seeding. Each patient underwent CHIPC three times after laparoscopeassisted perfusion catheters placing. The first session was completed in operative room under general anesthesia, 5% glucose solution was selected as perfusion liquid, and 1500 mg 5 fluorouracil (5FU) and 200 mg oxaliplatin were added in the perfusion solution. The second andthird sessions were performed in intensive care unit, 0.9% sodium chloride solution was selected as perfusion liquid, and 1500 mg 5FU was added in the perfusion solution alone. CHIPC was performed for 90 min at a velocity of 450600 mL/min and an in flow temperature of 43 ± 0.2℃.RESULTS: The intraoperative course was uneventful in all cases, and the mean operative period for laparoscopeassisted perfusion catheters placing was 80 min for each case. No postoperative deaths or complications related to laparoscopeassisted CHIPC occurred in this study. Clinically complete remission of ascites and related symptoms were achieved in 14 patients, and partial remission was achieved in 2 patients. During the followup, 13 patients died 29 mo after CHIPC, with a median survival time of 5 mo. Two patients with partial remission suffered from port site seeding and tumor metastasis,and died 2 and 3 mo after treatment. Three patients who are still alive today survived 4, 6 and 7 mo, respectively. The Karnofsky marks of patients (5090) increased significantly (P < 0.01) and the general status improved after CHIPC. Thus satisfactory clinical efficacy has been achieved in these patients treated by laparoscopic CHIPC. CONCLUSION: Laparoscopeassisted CHIPC is a safe, feasible and effective procedure in the treatment of debilitating malignant ascites induced by unresectable gastric cancers. | Ba, Ming-Chen Cui, Shu-Zhong Lin, Sheng-Qu Tang, Yun-Qiang Wu, Yin-Bing Wang, Bin Zhang, Xiang-Liang | 2010 | World Journal of Gastroenterology2010，16，15： | 50 |
| 3 | Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer:a randomized phase Ⅲ ARTIST trial显示文摘The efficacy and safety of bevacizumab with modified irinotecan,leucovorin bolus,and 5-fluorouracil intravenous infusion(mIFL) in the first-line treatment of metastatic colorectal cancer(mCRC) has not been well evaluated in randomized clinical trials in Chinese patients.We conducted a phrase Ⅲ trial in which patients with previously untreated mCRC were randomized 2:1 to the mIFL [irinotecan(125 mg/m2),leucovorin(20 mg/m2) bolus,and 5-fluorouracil intravenous infusion(500 mg/m2) weekly for four weeks every six weeks] plus bevacizumab(5 mg/kg every two weeks) group and the mIFL group,respectively.Co-primary objectives were progression-free survival(PFS) and 6-month PFS rate.In total,214 patients were enrolled.Our results showed that addition of bevacizumab to mIFL significantly improved median PFS(4.2 months in the mIFL group vs.8.3 months in the bevacizumab plus mIFL group,P < 0.001),6-month PFS rate(25.0% vs.62.6%,P < 0.001),median overall survival(13.4 months vs.18.7 months,P = 0.014),and response rate(17% vs.35%,P = 0.013).Grades 3 and 4 adverse events included diarrhea(21% in the mIFL group and 26% in the bevacizumab plus mIFL group) and neutropenia(19% in the mIFL group and 33% in the bevacizumab plus mIFL group).No wound-healing complications or congestive heart failure occurred.Our results suggested that bevacizumab plus mIFL is effective and well tolerated as first-line treatment for Chinese patients with mCRC.Clinical benefit and safety profiles were consistent with those observed in pivotal phase Ⅲ trials with mainly Caucasian patients. | Zhong-Zhen Guan Jian-Ming Xu Rong-Cheng Luo Feng-Yi Feng Li-Wei Wang Lin Shen Shi-Ying Yu Yi Ba Jun Liang Dong Wang Shu-Kui Qin Jie-Jun Wang Jing He Chuan Qi Rui-Hua Xu | 2011 | Chinese Journal of Cancer2011，30，10： | 48 |
| 4 | Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing,locally advanced or metastatic gastric or gastroesophageal junction cancer:a single-arm phase II study显示文摘Background:Current treatment options for human epidermal growth factor receptor 2(HER2)-overexpressing gastric cancer at third-line have shown limited clinical benefit.Further,there is no specific treatment for HER2 immunohistochemistry(IHC)2+and fluorescence in-situ hybridization-negative patients.Here,we report the efficacy and safety of a novel anti-HER2 antibody RC48 for patients with HER2-overexpressing,advanced gastric or gastroesophageal junction cancer.Methods:Patients with HER2-overexpressing(IHC 2+or 3+),locally advanced or metastatic gastric or gastroesophageal junction cancer who were under at least second-line therapy were eligible and received RC482.5 mg/kg alone every 2 weeks.The primary endpoint was the objective response rate(ORR)assessed by an independent review committee.Secondary endpoints included progressionfree survival(PFS),overall survival(OS),duration of response,time to progression,disease control rate,and safety.Results:Of 179 patients screened,125 were eligible and received RC48 treatment.The ORR was 24.8%(95%confidence interval[CI]:17.5%-33.3%).The median PFS and OS were 4.1 months(95%CI:3.7-4.9 months)and 7.9 months(95%CI:6.7-9.9 months),respectively.The most frequently reported adverse events were decreased white blood cell count(53.6%),asthenia(53.6%),hair loss(53.6%),decreased neutrophil count(52.0%),anemia(49.6%),and increased aspartate aminotransferase level(43.2%).Serious adverse events(SAEs)occurred in 45(36.0%)patients,and RC48-related SAEs were mainly decreased neutrophil count(3.2%).Seven patients had adverse events that led to death were not RC48-related.Conclusions:RC48 showed promising activity with manageable safety,suggesting potential application in patients with HER2-overexpressing,advanced gastric or gastroesophageal junction cancer who have previously received at least two lines of chemotherapy. | Zhi Peng Tianshu Liu Jia Wei Airong Wang Yifu He Liuzhong Yang Xizhi Zhang Nanfeng Fan Suxia Luo Zhen Li Kangsheng Gu Jianwei Lu Jianming Xu Qingxia Fan Ruihua Xu Liangming Zhang Enxiao Li Yuping Sun Guohua Yu Chunmei Bai Yong Liu Jiangzheng Zeng Jieer Ying Xinjun Liang Nong Xu Chao Gao Yongqian Shu Dong Ma Guanghai Dai Shengmian Li Ting Deng Yuehong Cui Jianmin Fang Yi Ba Lin Shen | 2021 | Cancer Communications2021，41，11： | 29 |
| 5 | Up-regulation of PIK3CA promotes metastasis in gastric carcinoma显示文摘AIM:To explore expressions of PIK3CA in the progression of gastric cancer from primary to metastasis and its effects on activation of phosphatidylinositol 3-kinase(PI3K)/Akt pathway.METHODS:mRNA and protein levels of PIK3CA were assessed,respectively,by real-time quantitative polymerase chain reaction and immunohistochemistry in specimens of normal gastric mucosa,primary foci and lymph node and distant metastasis of gastric cancer.Akt and phosphorylated Akt protein were also examined by Western blotting in these tissues,in order to analyze the effect of PIK3CA expression level changes on the activation of PI3K/Akt signaling pathway.RESULTS:PIK3CA mRNA in lymph node metastasis were approximately 5 and 2 folds higher,respectively,than that in the corresponding normal gastric mucosa and primary gastric cancer tissues(P<0.05),while no statistical significance was found compared with distant metastasis.Immunohistochemically,PIK3CA protein expression was discovered in 7(35%)specimens of 20 primary foci vs 10(67%)of 15 of lymph node metastasis or 11(61%)of 18 of distant metastasis(35%vs 67%,P=0.015;35%vs 61%,P=0.044).With the increased level of PIK3CA expression,the total Akt protein expression remained almost unchanged,but p-Akt protein was upregulated markedly.CONCLUSION:Increased expression of PIK3CA is expected to be a promising indicator of metastasis in gastric cancer.Up-regulation of PIK3CA may promote the metastasis of gastric cancer through aberrant activation of PI3K/Akt signaling. | Liu JF Zhou XK Chen JH Yi G Chen HG Ba MC Lin SQ Qi YC. | 2010 | World Journal of Gastroenterology2010，16，39： | 20 |
| 6 | Sodium fluoride induces apoptosis through reactive oxygen species-mediated endoplasmic reticulum stress pathway in Sertoli cells显示文摘Excessive fluoride exposure is known to contribute to reproductive system dysfunction,ultimately leading to pathological damage and apoptosis in cells. Although both oxidative and endoplasmic reticulum(ER) stresses have been implicated in fluorosis, the signaling pathways and their roles in sodium fluoride(Na F)-induced apoptosis of Sertoli cells have been sparsely described. In this study, oxidative damage, ER stress, and apoptosis were analyzed after Sertoli cells were treated with varying doses of Na F for 24 hr. Moreover, the antioxidant N-acetylcysteine(NAC) and pro-apoptotic transcription factor CHOP knockdown were used to clarify the precise interplay between reactive oxygen species(ROS), ER stress and their roles in NaF-induced apoptosis in Sertoli cells. The present study indicated that NaF significantly decreased cell viability and induced apoptosis in Sertoli cells. In addition, NaF exposure facilitated the accumulation of ROS and increased nuclear translocation of nuclear factor erythroid 2-related factor 2(Nrf2) in Sertoli cells. Treatment with NAC caused remarkable recovery from these NaF-induced responses. Meanwhile, excessive NaF triggered ER stress as evidenced by up-regulated glucose-regulated protein 78 k Da(GRP78), PKR-like ER kinase(PERK), phosphorylation of eukaryotic translation initiation factor 2α(p-eI F2α) and CCAAT/enhancer-binding protein-homologous protein(CHOP), without affecting total eukaryotic translation initiation factor 2α(e IF2α). NAC effectively blocked the activation of ER stress, suggesting that Na F-induced ROS is an early event that triggers ER stress. Taken together, the results demonstrate that the ROS-mediated ER stress pathway is the crucial mechanistic event involved in NaF-induced apoptosis of Sertoli cells. | Yang Yang Xinwei Lin Hui Huang Demin Feng Yue Ba Xuemin Cheng Liuxin Cui | 2015 | Journal of Environmental Sciences2015，27，4： | 10 |
| 7 | Malnutrition and Quality of Life in Chinese Cancer Patients: a Clinical Study of 23,994 Subjects显示文摘Background Malnutrition is common in patients with cancer,and can negatively impact their quality of life(QoL)and even survival.However,there is currently no large data available on the prevalence of malnutrition in Chinese cancer patients.This study evaluated the prevalence of malnutrition and the QoL of Chinese patients with locoregional,recurrent or metastatic cancer.Methods We conducted a nationwide observational,multi-center,hospital-based cross-sectional study within the Chinese Society of Nutritional Oncology(CSNO)Network.All of the patients were diagnosed with one of the following 18 different types of malignant tumors:lung cancer,gastric cancer,liver cancer,colorectal cancer,breast cancer,esophageal cancer,cervical cancer,endometrial cancer,nasopharyngeal carcinoma,malignant lymphoma,leukemia,pancreatic cancer,ovarian cancer,prostate cancer,bladder cancer,brain cancer,biliary tract malignant tumors or gastrointestinal stromal tumors.These patients were enrolled from 72 hospitals located in different regions of China.The patients’nutritional status was evaluated based on the body mass index(BMI),loss of bodyweight,laboratory measurements and patient generated-subjective global assessment(PG-SGA)scores.The cancer patients’physical status and QoL were assessed by the Karnofsky Performance Status(KPS)questionnaire and the European Organization for Research and Treatment of Cancer(EORTC)QLQ-C30 questionnaire,respectively.Results From December 2013 to April 2016,23,994 patients hospitalized for cancer treatment(such as surgery,chemotherapy or radiotherapy)were enrolled in the study.The patients included 12,494(52.9%)males and 11,124(47.1%)females.The mean age was 55.8±13.7 years.The proportions of patients in cancer stagesⅠ,Ⅱ,Ⅲ,Ⅳand uncertain were 11.5%,20.3%,27.5%,30.2%and 10.5%,respectively.Among the 23,994 inpatients,the proportions of patients who were underweight(BMI<18.5 kg/m2),normal(18.5 kg/m2 | Hong Xia Xu Chun Hua Song Zhen Ming Fu Chang Wang Zeng Qing Guo Yuan Lin Ying Ying Shi Wen Hu Yi Ba Su Yi Li Zeng Ning Li Kun Hua Wang Jing Wu Ying He Jia Jun Yang Cong Hua Xie Fu Xiang Zhou Xin Xia Song Gong Yan Chen Wen Jun Ma Su Xia Luo Zi Hua Chen Ming Hua Cong Hu Ma Chun Ling Zhou Wei Wang Qi Luo Yong Mei Shi Yu Mei Qi Hai Ping Jiang Wen Xian Guan Jun Qiang Chen Jia Xin Chen Yu Fang Lan Zhou Yong Dong Feng Rong Shao Tan Tao Li Jun Wen Ou Qing Chuan Zhao Jian Xiong Wu Min Weng Qing Hua Yao Jiu Wei Cui Wei Li Han Ping Shi the Investigation on Nutrition Status and Clinical Outcome of Common Cancers(INSCOC)Group | 2021 | Journal of Nutritional Oncology2021，6，1： | 8 |
| 8 | Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer(ESWN 01):a prospective randomized,multicenter,open-labeled phase 3 trial显示文摘Background:The benefit of systemic treatments in esophageal squamous cell carcinoma(ESCC)which has pro-gressed after chemotherapy is still uncertain and optimal regimens based on randomized trials have not yet been established.We aimed to compare the efficacy of irinotecan plus S-1 with S-1 monotherapy in recurrent or metastatic ESCC patients who had resistance to platinum-or taxane-based chemotherapy.Methods:We conducted a prospective randomized,multicenter,open-label,phase 3 trial in 15 centers across China.Eligible patients were adults with histologically confirmed recurrent or metastatic ESCC,and were randomly assigned(ratio,1:1)to receive either irinotecan plus S-1(intravenous infusion of irinotecan[160 mg/m2]on day 1 and oral S-1[80-120 mg]on days 1-10,repeated every 14 days)or oral S-1 monotherapy(80-120 mg/day on days 1-14,repeated every 21 days)using a central computerized minimization procedure.The primary endpoint was progression-free survival(PFS).Results:Between December 23,2014 and July 25,2016,we screened 148 patients and randomly assigned 123 patients to receive either irinotecan plus S-1 regimen(n=61)or S-1 monotherapy(n=62).After a median follow-up of 29.2 months(95%confidence interval[CI]17.5-40.9 months),the median PFS was significantly longer in the irinotecan plus S-1 group than in the S-1 monotherapy group(3.8 months[95%CI 2.9-4.3 months]vs.1.7 months[95%CI 1.4-2.7 months],hazard ratio=0.58,95%CI 0.38-0.86,P=0.006).The objective response rates were 24.6%in the irinotecan plus S-1 group and 9.7%in the S-1 monotherapy group(P=0.002).The patients in the irinotecan plus S-1 group presented with increased rates of grade 3-4 leukopenia(16.4%vs.0%),neutropenia(14.8%vs.1.6%),and nausea(4.9%vs.0%).No significant difference in grade 3-4 diarrhea and no treatment-related deaths were observed in both groups.Conclusions: The combination of irinotecan with S-1 was similarly tolerable but significantly prolonged PFS compared to S-1 monotherapy as a second- or third-line treatment in patients with recurrent or metastatic ESCC. | Jing Huang Binghe Xu Ying Liu Junxing Huang Ping Lu Yi Ba Lin Wu Yuxian Bai Shu Zhang Jifeng Feng Ying Cheng Jie Li Lu Wen Xianglin Yuan Changwu Ma Chunhong Hu Qingxia Fan Xi Wang | 2019 | Cancer Communications2019，39，1： | 8 |
| 9 | Expert consensus on maintenance treatment for metastatic colorectal cancer in China显示文摘The impact of maintenance therapy on progression-free survival and overall survival as well as quality of life of Chinese patients with metastatic colorectal cancer has long been under discussion.Recently,some phase III clinical trials have revealed that maintenance therapy can significantly prolong the progression-free survival while maintain an acceptable safety profile.Based on this evidence and common treatment practice in China,we now generated one Expert Consensus on Maintenance Treatment for Metastatic Colorectal Cancer in China to further specify the necessity of maintenance therapy,suitable candidates for such treatment,and appropriate regimens. | Rui-Hua Xu Lin Shen Jin Li Jian-Ming Xu Feng Bi Yi Ba Li Bai Yong-Qian Shu Tian-Shu Liu Yu-Hong Li Chun-Mei Bai Xiang-Lin Yuan Jun Zhang Gong Chen Ai-Ping Zhou Ying Yuan Xi-Jing Wang Xiao-Ping Qian Yan-Hong Deng | 2016 | Chinese Journal of Cancer2016，35，1： | 8 |
| 10 | Potential Anti-cancer Activity of Furanodiene显示文摘Objective:To study the anti-tumor activities of furanodiene(C15H20O),a primary sesquiterpene compound isolated from the essential oil of the rhizome of Curcuma wenyujin YH Chen et C.Ling(Wen Ezhu),in vitro and in vivo.Methods:In vitro MTT assay was used to further study the effects of time and dosage on anti-proliferation of furanodiene against the sensitive Hela,Hep-2,HL-60,U251 cells,based on the cytotoxic effects of furanodiene on 12 human malignant tumor cell lines with the essential oil of Wen Ezhu as control.,and the half-inhibitory concentration(IC50) was observed.In vivo uterine cervix(U14) tumor cell was selected and the conventional assay method of anti-tumor activity was employed.Furanodiene liposome was administered intraperitoneally,and tumor-inhibitory rate,thymus and spleen indexes were observed.Results:The inhibitive effects on cell proliferation were shown in all of the twelve cell lines and the cytotoxic effects of furanodiene against Hela,Hep-2,HL-60,U251 cells were observed after 12 h of administration,the effect could last for at least 48 h in a dose dependent manner,and the IC50 values were 0.6,1.7,1.8,7.0 μg/ml,respectively.Furanodiene was also found to show inhibitive effects on the proliferation of uterine cervix(U14) tumor induced in mice.The tumor inhibition rates were 36.09%(40 mg/kg),41.55%(60 mg/kg),58.29%(80 mg/kg),respectively.Conclusion:Furanodiene is one of primary anti-cancer active components in the essential oil of Wen Ezhu,and also a very effective agent against uterine cervix cancer,and has protection effect on the immune function. | Zhen-zhen Ba Yan-ping Zheng Hui Zhang Xiu-yan Sun Dong-hai Lin | 2009 | Chinese Journal of Cancer Research2009，21，2： | 7 |
| 11 | Validity of the Chinese Version of the Patient-Generated Subjective Global Assessment (PG-SGA) in Lung Cancer Patients显示文摘The prevalence of malnutrition is high among oncology patients in China. Although the Patient- Generated Subjective Global Assessment (PG-SGA) is widely recognized as an important nutritional assessment tool, it has not been validated for Chinese cancer patients. The purpose of this study was to conduct an analysis of nutrition screening and assessment data to validate the Chinese version of the PG-SGA in Chinese patients with lung cancer. This was an observational, cross-sectional study of 2,000 consecutive adult patients with lung cancer treated at several tertiary hospitals in China. Anthropometric and patient descriptive data were collected. The PG-SGA generated a score for the nutritional risk and a global rating for the nutritional status. The internal consistency, external consistency, and construct validity were evaluated, and a known-groups comparison and principal component analyses were conducted to evaluate the reliability and validity of the PG-SGA. The known-groups comparison demonstrated the ability of the PG-SGA to differentiate lung cancer patients of different nutritional and body mass index (BMI) groups. A confirmatory factor analysis supported the original four-factor structure of the PG-SGA. In terms of the internal and external consistency, the PG-SGA demonstrated intra-class correlation coefficients (ICC) up to 0.987. Alternative form validity was also demonstrated between Box 4 of the PG-SGA and the Karnofsky Performance Status score, with excellent external consistency (r = 0.972, P < 0.001). The construct validity was supported, and selected questionnaire dimensions were evident in the principal component analysis. Significant Spearman correlations (P < 0.001) were demonstrated. The Chinese version of the PG-SGA demonstrated significant reliability and sufficient exploratory properties to support its validity. It seems to be a valid tool that can be used to access the nutritional status of Chinese lung cancer patients. The validity of the PG-SGA in Chinese cancer patients warrants further investigation in other cancer types. | Zhen Ming Fu Hong Xia Xu Chun Hua Song Wei Li Zeng Qing Guo Yuan Lin Ying Ying Shi Wen Hu Yi Ba Su Yi Li Zeng Ning Li Kun Hua Wang Jing Wu Ying He Jia Jun Yang Cong Hua Xie Xin Xia Song Gong Yan Chen Wen Jun Ma Su Xia Luo Zi Hua Chen Ming Hua Cong Hu Ma Chun Ling Zhou Wei Wang Qi Luo Yong Mei Shi Yu Mei Qi Hai Ping Jiang Wen Xian Guan Jun Qiang Chen Jia Xin Chen Yu Fang Lan Zhou Yong Dong Feng Rong Shao Tan Tao Li Jun Wen Ou Qing Chuan Zhao Jian Xiong Wu Chang Wang Han Ping Shi The Investigation on Nutrition Status and Clinical Outcome of Common Cancers (INSCOC) Group | 2016 | Journal of Nutritional Oncology2016，1，1： | 7 |
| 12 | Large-area high quality PtSe2 thin film with versatile polarity显示文摘Two-dimensional(2D)materials have attracted increasing attention for their outstanding structural and electrical properties.However,for mass-production of field effect transistors(FETs)and potential applications in integrated circuits,large-area and uniform 2D thin films with high mobility,large on-off ratio,and desired polarity are needed to synthesize firstly.Here,a transfer-free growth method for platinum diselenide(PtSe2)films has been developed.The PtSe2 films have been synthesized with various thicknesses in centimeter-sized scale.Typical FET made from a few layer PtSe2 show p-type unipolar,with a high field-effect hole mobility of 6.2 cm^(2) V^(−1) s^(−1) and an on-off ratio of 5×10^(3).The versatile semimetal-unipolar-ambipolar transition in synthesized PtSe2 films is also firstly observed as the thickness thinning.This work realizes the large-scale preparation of PtSe2 with prominent electrical properties and provides a new strategy for polarity's modulation. | Wei Jiang Xudong Wang Yan Chen Guangjian Wu Kun Ba Ningning Xuan Yangye Sun Peng Gong Jingxian Bao Hong Shen Tie Lin Xiangjian Meng Jianlu Wang Zhengzong Sun | 2019 | InfoMat2019，1，2： | 5 |
| 13 | Validity of the Chinese Version of the Patient-Generated Subjective Global Assessment (PG-SGA) in Gastric Cancer Patients显示文摘Purpose Malnutrition is severe among gastric cancer patients in China. While the Patient-Generated Subjective Global Assessment (PG-SGA) is a widely used nutritional assessment tool, the validation for Chinese patients with gastric cancer has not been performed yet. The aim of this research is to validate the Chinese version of the PGSGA in Chinese gastric cancer patients by conducting analyses of nutrition screening and assessment data. Methods Two thousand consecutive adult patients with gastric cancer were included in this observational, cross-sectional study in several tertiary hospitals in China. A survey was made among those patients, which included several questionnaires and some anthropometric parameters. We calculated the parameters to validate the use of PG-SGA categorizing the nutritional status of gastric cancer patients. Then we performed statistical analysis to evaluate the internal consistency, external consistency, and construct validity. Results This study verified the ability of the PG-SGA to differentiate gastric cancer patients into different nutritional groups. The confirmatory factor analysis verified the original four-factor structure of the PG-SGA. The internal and external consistency was measured by a concordance analysis which showed an intraclass correlation coefficients (ICC) of 0.987. The correlations of the Box 4 score with the Karnofsky performance status score demonstrated alternative form validity with good external consistency (Pearson, r = 0.643, P < 0.001). All three anthropometric dimensions of the PG-SGA were supported by principal component analysis. Spearman correlations (P < 0.001) were significant in the majority of tests. Conclusion The Chinese version of the PG-SGA is a valid tool to access the patients’ nutritional status for Chinese gastric patients. | Zhen Ming Fu Hong Xia Xu Chun Hua Song Wei Li Zeng Qing Guo Yuan Lin Ying Ying Shi Wen Hu Yi Ba Su Yi Li Zeng Ning Li Kun Hua Wang Jing Wu Ying He Jia Jun Yang Cong Hua Xie Xin Xia Song Gong Yan Chen Wen Jun Ma Su Xia Luo Zi Hua Chen Ming Hua Cong Hu Ma Chun Ling Zhou Wei Wang Qi Luo Yong Mei Shi Yu Mei Qi Hai Ping Jiang Wen Xian Guan Jun Qiang Chen Jia Xin Chen Yu Fang Lan Zhou Yong Dong Feng Rong Shao Tan Tao Li Jun Wen Ou Qing Chuan Zhao Jian Xiong Wu Chang Wang Han Ping Shi The Investigation on Nutrition Status and Clinical Outcome of Common Cancers (INSCOC) Group | 2018 | Journal of Nutritional Oncology2018，3，4： | 5 |
| 14 | Brittleness characteristics of tight oil siltstones显示文摘岩石易碎物直接影响水库断裂,它的评估为建立是必要的在水库改过以前折断条件。动态、静态的易碎物数据在 Songliao 盆从 Qingshankou 形成的 siltstones 被收集。易碎塑料的转变基于压力紧张关系被调查。结果建议静态的有弹性的参数计算的易碎物索引否定地与压力落下系数和定义为规范的幼仔模量和泊松比率的一般水准的易碎物索引 B 2, 被相关,强烈与压力落下被相关。易碎物索引 B 2, 幼仔模量,和泊松比率与易碎的矿物质内容相关;也就是说石英,碳酸盐,和黄铁矿。我们也基于索引 B 2 调查了在毛孔液体和孔和动态易碎的特征之间的关联。毛孔液体增加岩石和还原剂易碎物的粘性;而且与增加孔,岩石易碎物减少。浸透气体的 siltstone 易碎物索引在浸透油或浸透水的 siltstone 比那高;在浸透油、浸透水的 siltstone 的易碎物索引的差别是很小的。由比较岩石力学和超声的实验,我们比从超声的实验获得了的发现从岩石力学实验获得的易碎物索引小;不过,两个都与象他们的差别一样增加孔减少。没有影响他们,超声的波浪通过岩石标本宣传,而岩石力学实验是破坏的并且导致 microcracking 和孔增加;因而,低孔的岩石的易碎物被内部 microcrack 系统的形成影响。 | Tan Wen-Hui Ba Jing Guo Meng-Qiu Li Hui Zhang Lin Yu Ting Chen Hao | 2018 | Applied Geophysics2018，15，2： | 5 |
| 15 | Velocity field of wave-induced local fluid flow in double-porosity media显示文摘Under the excitation of elastic waves,local fluid flow in a complex porous medium is a major cause for wave dispersion and attenuation.When the local fluid flow process is simulated with wave propagation equations in the double-porosity medium,two porous skeletons are usually assumed,namely,host and inclusions.Of them,the volume ratio of inclusion skeletons is low.All previous studies have ignored the consideration of local fluid flow velocity field in inclusions,and therefore they can not completely describe the physical process of local flow oscillation and should not be applied to the situation where the fluid kinetic energy in inclusions cannot be neglected.In this paper,we analyze the local fluid flow velocity fields inside and outside the inclusion,rewrite the kinetic energy function and dissipation function based on the double-porosity medium model containing spherical inclusions,and derive the reformulated Biot-Rayleigh(BR)equations of elastic wave propagation based on Hamilton’s principle.We present simulation examples with different rock and fluid types.Comparisons between BR equations and reformulated BR equations show that there are significant differences in wave response characteristics.Finally,we compare the reformulated BR equations with the previous theories and experimental data,and the results show that the theoretical results of this paper are correct and effective. | BA Jing ZHANG Lin SUN WeiTao HAO ZhaoBing | 2014 | Science China(Physics,Mechanics & Astronomy)2014，57，6： | 4 |
| 16 | Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer:a multicenter,randomized,double-blinded,placebo-controlled,phaseⅡclinical trial显示文摘Background: Metastatic colorectal cancer(mCRC) patients with progressive disease after all available standard therapies need new medication for further treatment. Famitinib is a small-molecule multikinase inhibitor, with promising anticancer activities. This multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial was designed to evaluate the safety and efficacy of famitinib in mCRC.Methods: Famitinib or placebo was administered orally once daily. The primary endpoint was progression-free survival(PFS). Secondary endpoints included objective response rate(ORR), disease control rate(DCR), overall survival(OS), quality-of-life(QoL), and safety.Results: Between July 18,2012 and Jan 22,2014, a total of 167 patients were screened, and 154 patients were randomized in a 2:1 ratio to receive either famitinib(n = 99) or placebo(n = 55). The median PFS was 2.8 and 1.5 months in the famitinib and placebo groups(hazard ratio = 0.60,95% confidence interval = 0.41-0.86, P = 0.004). The DCR was 59.8% and 31.4%(P = 0.002) and the ORR was 2.2% and 0.0%(P = 0.540) in the famitinib and placebo groups,respectively. The most frequent grade 3-4 adverse events were hypertension(11.1%), hand-foot syndrome(10.1%),thrombocytopenia(10.1%) and neutropenia(9.1%). Serious adverse events occurred in 11(11.1%) patients in the famitinib group and 5(9.1%) in the placebo group(P = 0.788). The median OS of the famitinib and placebo groups was 7.4 and 7.2 months(P = 0.657).Conclusion: Famitinib prolonged PFS in refractory mCRC patients with acceptable tolerability.Trial registration This study was registered on ClinicalTrials.gov(NCT01762293) and was orally presented in the 2015 ASCO-Gastrointestinal | Rui-Hua Xu Lin Shen Ke-Ming Wang Gang Wu Chun-Mei Shi Ke-Feng Ding Li-Zhu Lin Jin-Wan Wang Jian-Ping Xiong Chang-Ping Wu Jin Li Yun-Peng Liu Dong Wang Yi Ba Jue-Ping Feng Yu-Xian Bai Jing-Wang Bi Li-Wen Ma Jian Lei Qing Yang Hao Yu | 2017 | Chinese Journal of Cancer2017，36，12： | 4 |
| 17 | 考虑活塞-活塞销系统结构变形及空穴机理的活塞销润滑分析(英文)显示文摘目的:建立柔性结构下的活塞-活塞销耦合系统的润滑模型,分析活塞销的形貌和结构对活塞销的摩擦磨损的影响,为活塞销的设计提供参考依据。创新点:1.建立柔性结构下的活塞销多体动力学模型,将空穴理论与活塞销润滑模型耦合,研究活塞销的润滑情况;2.考虑活塞的热变形,使得活塞销润滑情况更贴近于实际;3.将活塞销的干接触位置与实际活塞销磨损位置进行对比,验证活塞销的易磨损部位。方法:1.基于有限元理论构建活塞-活塞销耦合系统润滑分析所需的有限元模型(图3);2.基于模态缩减理论建立活塞-活塞销耦合系统多体动力学仿真模型,将热变形耦合于活塞销型线中(图4);3.分析活塞销的基本润滑特性,比较空穴现象对润滑的影响(图12–15);4.分析不同型面的活塞销的润滑特性,比较各种型线下活塞销的润滑情况(图16–18);5.分析不同销孔内径下活塞销的润滑特性(图21和22)。结论:1.在活塞销润滑问题分析中,考虑到有限差分网格密度和有限元网格密度不一致,采用节点插值算法解决压力不收敛问题;2.从压力作用于活塞顶部的形式方面分析,研究活塞销易发生干接触的部位;3.对比分析是否考虑空穴机理的活塞销润滑特性;研究结果表明,由于油膜破裂导致油膜不能承受载荷,且承受油膜压力位置的密度为油膜密度,其它区域小于油膜密度;4.对比不同型线下活塞销的干接触情况,为活塞销的设计提供参考依据;5.研究不同活塞销孔内径下的润滑,考虑活塞销的热变形,使得润滑分析更贴近实际。 | Lin BA Zhen-peng HE Yue-hui LIU Gui-chang ZHANG | 2015 | Journal of Zhejiang University-Science A(Applied Physics & Engineering)2015，16，6： | 4 |
| 18 | Penile prosthesis implantation in Chinese patients wit severe erectile dysfunction: 10-year experience显示文摘我们回顾地与严重可勃起的机能障碍(SED ) 在中国病人评估了阴茎修复术培植(PPI ) 的临床的结果。从 2000 年 7 月到 2011 年 12 月, 224 个病人(吝啬的年龄:35.9 ± 11.8 年,变化:20-75 年) 在我们的中心根据标准 PPI 过程由富有经验的外科医生与 SED 经历了 PPI。韧性的修复术(AMS 650 ) 在 45 种情况中被植入(20.1 %) ,并且三片的可膨胀的修复术(AMS 700 CXM 或 AMS 700 CXR ) 在 179 种情况中被植入(79.9 %) 。包括手术后的复杂并发症,临床的功效和夫妇满足,外科的结果被评估在上比手术后地使用医药记录抽象的 6 个月, IIEF-5,生活(QoL ) 的质量分数,和病人 / 搭挡的性满足分数由 Bhojwani 等求婚了。为学习合格的 224 个病人, 201 使遭到(89.7 %) 完成的后续。所有能与吝啬的手术后的 IIEF-5 病人执行性交柱子 PPI, QoL 分数是 20.02 ± 2.32 和 5.28 ± 0.76,分别地它显著地与外科手术前的分数相比被改进(6.29 ± 1.5 和 2.13 ± 0.84, P< 0.01 ) 。201 个人,机械失灵发生在四种情况中(2.0 %) 并且三个盒子被重新植入新设备,和二个盒子(1.0 %) 开发了阴茎的温和弯曲。有感染的阴囊的侵蚀与糖尿病 mellitus 发生在一种情况中(0.5 %) 并且植入的 AMS 的要求的完全的移动 700 CXM。令人满意的性交被 178 个人两次至少每月报导(88.6 %) ,并且对 PPI 外科的全面满足被 89.0 % 报导;人和 82.5 %搭挡。在三片的可膨胀的修复术组的耐心的满足比在韧性的修复术组高(P< 0.05 ) 。然而,在 prostheses 的类型之间,满足没在搭挡调查不同。PPI 是一种安全、有效的治疗选择因为有 SED 和富有经验的外科医生的中国病人根据标准 PPI 执行 PPI 过程能减少 PPI 的手术后的复杂并发症并且能改进耐心的满足比率和 QoL。 | Wei-Dong Song Yi-Ming Yuan Wan-Shou Cui Alex K Wu Yi-Chen Zhu Jing Liu Lin Wang Guang-Yi Ba Jing Peng Zhi-Chao Zhang Bing Gao Ying-Lu Guo Tom F Lue Zhong-Cheng Xin | 2013 | Asian Journal of Andrology2013，15，5： | 3 |
| 19 | Study protocol of the Asian XELIRI ProjecT(AXEPT):a multinational,randomized,non-inferiority,phase Ⅲ trial of second-line chemotherapy for metastatic colorectal cancer, comparing the eicacy and safety of XELIRI with or without bevacizumab versus FOLFIRI w显示文摘Background: Capecitabine and irinotecan combination therapy(XELIRI) has been examined at various dose levels to treat metastatic colorectal cancer(m CRC). Recently, in the Association of Medical Oncology of the German Cancer Society(AIO) 0604 trial, tri?weekly XELIRI plus bevacizumab, with reduced doses of irinotecan(200 mg/m^2 on day 1) and capecitabine(1600 mg/m^2 on days 1–14), repeated every 3 weeks, has shown favorable tolerability and eicacy which were comparable to those of capecitabine and oxaliplatin(XELOX) plus bevacizumab. The doses of capecit?abine and irinotecan in the AIO trial are considered optimal. In a phase I/II study, XELIRI plus bevacizumab(BIX) as second?line chemotherapy was well tolerated and had promising eicacy in Japanese patients.Methods: The Asian XELIRI Projec T(AXEPT) is an East Asian collaborative, open?labelled, randomized, phase Ⅲ clinical trial which was designed to demonstrate the non?inferiority of XELIRI with or without bevacizumab versus standard FOLFIRI(5?fluorouracil, leucovorin, and irinotecan combination) with or without bevacizumab as second?line chemo?therapy for patients with m CRC. Patients with 20 years of age or older, histologically conirmed m CRC, Eastern Coop?erative Oncology Group performance status 0–2, adequate organ function, and disease progression or intolerance of the irst?line regimen will be eligible. Patients will be randomized(1:1) to receive standard FOLFIRI with or with?out bevacizumab(5 mg/kg on day 1), repeated every 2 weeks(FOLIRI arm) or XELIRI with or without bevacizumab(7.5 mg/kg on day 1), repeated every 3 weeks(XELIRI arm). A total of 464 events were estimated as necessary to show non?inferiority with a power of 80% at a one?sided α of 0.025, requiring a target sample size of 600 patients. The 95% conidence interval(CI) upper limit of the hazard ratio was pre?speciied as less than 1.3.Conclusion: The Asian XELIRI Projec T is a multinational phase III trial being conducted to provide evidence for XELIRI with or without bevacizumab as a second?line treatment option of mCRC. | Masahito Kotaka Ruihua Xu Kei Muro Young Suk Park Satoshi Morita Satoru Iwasa Hiroyuki Uetake Tomohiro Nishina Hiroaki Nozawa Hiroshi Matsumoto Kentaro Yamazaki Sae-Won Han Wei Wang Joong Bae Ahn Yanhong Deng Sang-Hee Cho Yi Ba Keun-Wook Lee Tao Zhang Taroh Satoh Marc E.Buyse Baek-Yeol Ryoo Lin Shen Junichi Sakamoto Tae Won Kim | 2016 | Chinese Journal of Cancer2016，35，12： | 3 |
| 20 | Extension Protocol for the Investigation on Nutrition Status and Clinical Outcome of Patients with Common Cancers in China(INSCOC)Study:2021 update显示文摘Background Malnutrition is common in patients with cancer,and this adversely affects the survival and quality of life of patients.Chinese Society for Nutritional Oncology issued a multi-center,large-scale,long-term follow-up prospective study,the Investigation on Nutrition Status and Clinical Outcome of Patients with Common Cancers in China(INSCOC study)since 2013.This is an extension to the previous 2013-2020 study protocol.This study still sought to:①address the prognostic impact of nutritional factors and quality of life on cancer patient survival;②describe the overall and cancer-specific incidence and/or distribution of malnutrition and different measurements of patient quality of life.Methods and study design This is an observational,multi-centered,hospital-based prospective cohort study.Data collection will be performed at baseline(within 48 hours after patient admission),during the hospital stay and 30 days after hospital admission.Follow-up will be conducted for 1-20 years after enrollment.The primary outcome will be the all-cause mortality/overall survival,and secondary outcomes will be the length of hospital stay and costs of hospitalization.Study factors will include demographic characteristics,tumor characteristics,information about chronic diseases,hematological measurements(e.g.,red blood cell count,total lymphocyte counts,hemoglobin,albumin,prealbumin,creatinine,C-reactive protein,IL-6),anthropometric measurements(e.g.,height,weight,arm circumference,arm muscle circumference,triceps skinfold thickness,and waist circumference),body composition parameters,PG-SGA scores,quality of life(as indicated by the QLQ-C30 questionnaire),muscle mass(as indicated by the calf circumference),muscle strength(as indicated by the handgrip strength),muscle function(as indicated by the six-meter walking speed test)and physical status assessments(as indicated by the Karnofsky Performance Status scores).This clinical study protocol was approved by local Ethics Committees of all the participating hospitals.Written informed consent is required for each subject included.Discussion This multi-center,large-scale,long-term follow up prospective study will help improve the diagnosis of malnutrition in cancer patients and identify the risk factors associated with adverse clinical outcomes.The anticipated results of this study will highlight the need for a truly scientific appraisal of nutrition therapy in Chinese oncology populations,and finally help treat the potentially reversible elements of malnutrition in cancer patients to improve their clinical outcomes in the future. | Hong Xia Xu Chun Hua Song Liang Yu Yin Chang Wang Zhen Ming Fu Zeng Qing Guo Yuan Lin Ying Ying Shi Wen Hu Yi Ba Su Yi Li Zeng Ning Li Kun Hua Wang Jing Wu Ying He Jia Jun Yang Cong Hua Xie Fu Xiang Zhou Xin Xia Song Gong Yan Chen Wen Jun Ma Su Xia Luo Zi Hua Chen Zhi Kang Chen Ming Hua Cong Hu Ma Chun Ling Zhou Wei Wang Qi Luo Yong Mei Shi Yu Mei Qi Hai Ping Jiang Wen Xian Guan Jun Qiang Chen Xiang Hua Wu Jia Xin Chen Yu Fang Lan Zhou Yong Dong Feng Rong Shao Tan Tao Li Jun Wen Ou Qing Chuan Zhao Jian Xiong Wu Min Weng Qing Hua Yao Ya Yin Yu Quan Jun Lyu Hong Qiu Ming Liu Wei Li Han Ping Shi The Investigation on Nutrition Status and Clinical Outcome of Common Cancers(INSCOC)Group | 2022 | Journal of Nutritional Oncology2022，7，2： | 3 |
您所在的机构暂未开通此部分的功能，请联系管理员